Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP4Z1 | Q86W10 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.45 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3800271 | 0.87 | GAA (0.56) | MAOBL3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL11716689 | 0.86 | MEN1 (0.49) | MAOBL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL10411098 | 0.85 | MAOB (0.51) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL7414630 | 0.85 | CYP4F2 (0.50) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL8935104 | 0.85 | ALDH1A1 (0.53) | MAPTL3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL1403568 | 0.84 | PTGS1 (0.67) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| Methane SCHEMBL10411744 | 0.84 | MAOB (0.50) | MAOBMAPTL3MBTL1RAB9ASMN1; SMN2 | |
| SCHEMBL1107146 | 0.82 | CYP4Z1 (0.57) | MAPTL3MBTL1SMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL24368273 | 0.80 | MAOB (0.50) | MAOBL3MBTL1RAB9ASMN1; SMN2NPC1 | |
| SCHEMBL29518276 | 0.80 | MAOB (0.50) | MAOBL3MBTL1RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | MERCK SHARP & DOHME LLC | 2011-03-17 | — | — | US | disclosed |
| US-5789415-A | Azacyclic-heterocyclic compounds as angiotension II receptor antagonists | PFIZER INC. (US) | 1998-08-04 | — | — | US | disclosed |
| WO-1995002596-A1 | AZACYCLIC-HETEROCYCLIC COMPOUNDS AS ANGIOTENSIN II RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 1995-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065634-A1 | GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR THEIR USE | GLP1R, GCGR, GIPR | MAOB 1247/4885MAPT 4808/4885L3MBTL1 2096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.